• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Mar­ket­ingRx Matchup: How Ab­b­Vie and Bio­haven ads rank in head-to-head mi­graine chal­lenge

4 years ago
Pharma
Marketing

Q&A: Organon chief com­mu­ni­ca­tions of­fi­cer Wendy Lund talks about the Mer­ck spin­off, women’s health and why it ...

4 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Pfiz­er re-ups pneu­mo­nia ads as Mer­ck threat looms; Re­al Chem­istry founder CEO Jim Weiss steps ...

4 years ago
Pharma
Marketing

Mer­ck pumps the brakes on two more PhI­II tri­als for its lead an­ti-HIV drug

4 years ago
R&D

vTv Ther­a­peu­tics cuts 65% of em­ploy­ees in shake­up; Freenome bags $300M in Se­ries D to ex­pand mul­ti­omics plat­form

4 years ago
News Briefing

Lon­don AI-fo­cused Benev­o­len­tAI go­ing pub­lic in Eu­rope via $438M SPAC deal

4 years ago
Financing
AI

Aca­dia touts late-stage win for its Rett syn­drome drug, edg­ing out a lead against its com­peti­tors

4 years ago
R&D

Covid-19 roundup: Plant-based shot proves safe, 71% ef­fi­ca­cious in PhI­II; Bourla ex­pects an­tivi­ral to launch this ...

4 years ago
Coronavirus

Can a new Eu­ro­pean biotech make an ADC bet­ter than Pad­cev? In­vestors are putting up al­most $100M to find out

4 years ago
Financing

Richard Lern­er, an­ti­body pi­o­neer and long­time pres­i­dent of Scripps Re­search, dies at 83

4 years ago
People

'We're in': Roche and Genen­tech join forces on a multi­bil­lion-dol­lar dis­cov­ery pact with a brash AI up­start

4 years ago
Deals
Bioregnum

Ice­landic bil­lionare's biosim­i­lar com­pa­ny rais­es $450M, preps for Nas­daq launch with SPAC merg­er

4 years ago
Financing
Startups

As­traZeneca grabs PhI­II AT­TR drug from Io­n­is — in­fus­ing $200M cash in­to strug­gling part­ner

4 years ago
Deals

Al­ways busy, Gary Glick re­cruits Or­biMed in a mas­sive $218M Se­ries A for enig­mat­ic da­ta sci­ence biotech

4 years ago
People
Financing

Spe­cial re­port: Meet 20 ex­tra­or­di­nary women who are su­per­charg­ing bio­phar­ma R&D

4 years ago
People
Special

Transpa­cif­ic AI biotech makes its Se­ries A de­but — putting $86M in the bank

4 years ago
Financing
Startups

Ap­ple Tree Part­ners leaps across the pond to launch a UK biotech look­ing to crack the se­crets of den­drit­ic cells

4 years ago
Financing
Startups

WHO rec­om­mends against the use of con­va­les­cent plas­ma for Covid-19

4 years ago
Coronavirus

Dig­i­tal clut­ter threat­ens phar­ma-to-physi­cian re­la­tion­ships in shift to next era of com­mu­ni­ca­tions

4 years ago
Pharma
Marketing

Klick Health hands out $100 bills in an­nu­al hol­i­day greet­ing that’s turned in­to de­fault re­cruit­ing tool

4 years ago
Pharma
Marketing

Seat­tle biotech clos­es $18M Se­ries B — and ac­quires a com­pa­ny; An­oth­er George Church alum launch­es up­start

4 years ago
News Briefing

FDA slams Reata's kid­ney drug as in­ef­fec­tive ahead of ad­comm meet­ing

4 years ago
Pharma
FDA+

Recor­dati ac­quires EU­SA Phar­ma and its 4 rare dis­ease drugs, but an­a­lysts ques­tion strat­e­gy be­hind the deal

4 years ago
Deals

Bolt Bio goes bust as in­vestors boo sin­gle re­sponse in ear­ly test against HER2-ex­press­ing tu­mors

4 years ago
R&D
First page Previous page 613614615616617618619 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times